Skip to content

The Gut Microbiota of Bipolar and Depression

Altered Fecal Microbiota Composition in Patients With Major Depressive Disorder and Bipolar Disorder

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03062332
Enrollment
240
Registered
2017-02-23
Start date
2020-01-16
Completion date
2022-11-30
Last updated
2021-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Major Depressive Disorder

Brief summary

Background: The gut microbiome is emerging as an important factor in regulating mental health yet it remains unclear what the target should be for psychiatric treatment. Investigators aim at elucidating the complement of the gut microbiome community for individuals with Major Depressive disorder (MDD) and Bipolar disorder (BD) relative to controls, and test for relationships with symptoms. Methods: Investigators prospect to recruit subjects including patients and controls amount to 240. All subjects will be collected for blood and stool samples,assessed by clinical scales. Finally, analyzing the correlation among the metabolon in blood, microbiota in stool and clinical scales to obtain the possible interaction between diseases and gut microbiota.

Detailed description

Background: MDD (Major Depressive disorder) and BD (Bipolar disorder), whose specific pathogenesis is still unclear, are both a multi-factorial disease being caused by biological, psychological and social factors. Accumulating evidence suggests that gut microbiota play an important role in brain functions and in the pathogenesis of neuropsychiatric diseases, such as autism, anxiety, as well as depression. No study has thus far compared the human gut microbiota among BD, MDD and the healthy control (HC). The aim of this study is to compare the composition of fecal microbiota among BD, MDD and HC. Furthermore, investigators aim at identifying direct correlations between human fecal microbiota (as a proxy for gut microbiota) and symptoms. Methods: 1. Investigators aim at recruiting human subjects in total 240, which including mania episode of bipolar disorder (40), depressive episode of bipolar disorder (40), mixed episode of bipolar disorder (40), first episode of major depressive disorder (40), recurrent episode of major depressive disorder (40), and healthy control (40). All patients, diagnosed according to the research criteria of the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), come from The First Affiliated Hospital of Xi'an Jiaotong University and controls are healthy volunteers. 2. Collecting blood and stool samples, evaluating clinical scales including Montgomery-Asberg Depression Scale (MADRS), Young Mania Rating Scale (YMRS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), Measurement And Treatment Research To Improve Cognition In Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB), Clinical Global Impression (CGI) are all finished in first day after threshold. 3. Measure the metabolon in blood such as S-CFA, and gut microbiota. 4. Using Statistical Program for Social Sciences (SPSS) to compare general and clinical data among groups and analyze the correlation between the microbiota and symptoms.

Interventions

GENETICFaecal genome

Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.

Sponsors

First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Conforms to the diagnosis of bipolar disorder or major depressive disorder. * Take antibiotics continuously less than 3 days in recent 3 months. * 17.5≦BMI≦30 * Age≦65

Exclusion criteria

* who is diagnosed with physical diseases and other mental diseases. * pregnant or lactational women * who is diagnosed with mental retardation.

Design outcomes

Primary

MeasureTime frameDescription
Composition of the gut microbiota3 monthsThe relative richness of the species, %

Secondary

MeasureTime frameDescription
metabolon3 monthsthe concentration of short-chain fatty acid(S-CFA), μg/ml

Countries

China

Contacts

Primary ContactXiancang Ma, professor
maxiancang@163.com13002951782
Backup ContactWei Wang
xianwv@sina.com86-13991985805

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026